I thought it was a bit odd for James to promise data after just one group, especially since the trials start with the lowest dose. That's alot of paperwork for all involved and alot of pauses in trading, not to mention isolated data, if we get results after every group. I suspect an interim readout may be a little while away yet. But I may be wrong.
